May 12, 2011

A blood pressure drug made by Swiss drug maker Novartis has won an award from the Healthcare Compliance Packaging Council.

May 6, 2011

The Food and Drug Administration has approved a drug made by Novartis as the first treatment for advanced pancreatic neuroendocrine tumors, Novartis said Thursday.

May 4, 2011

Novartis is making big investments in biosimilars, CEO Joe Jimenez said in an interview with Fortune magazine.

May 4, 2011

The Food and Drug Administration has approved a generic oral contraceptive made by Sandoz, the generics arm of Swiss drug maker Novartis said Wednesday.

April 27, 2011

OTC Perspectives magazine on Tuesday named its third annual list of "Top OTC/HBA Marketers of the Year."

April 25, 2011

Mylan has launched a generic treatment for breast cancer, the drug maker said Monday.

April 11, 2011

The Food and Drug Administration has approved an oral contraceptive made by Sandoz, the company said Friday.

April 5, 2011

Mylan subsidiary Bioniche Pharma has launched an injectable treatment for a rare metabolic disorder, Mylan said Tuesday.

March 24, 2011

The Food and Drug Administration has extended its regulatory review period for Novartis' new drug application for its once-daily, long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, as well as chronic bronchitis and/or emphysema, the drug maker said.

March 24, 2011

Sandoz has introduced an authorized generic version of a herpes treatment made by parent company Novartis, the company said Thursday.

March 22, 2011

A subsidiary of Watson Pharmaceuticals has launched a treatment for herpes infections, the company said Monday.

March 7, 2011

The OTC Pain Relief Ingredient Guide breaks down the indication, active ingredients, purpose and dosage of OTC internal and external analgesics.

March 2, 2011

A group of drug makers have sued Mylan over its attempt to gain Food and Drug Administration approval for a generic menopause drug, Mylan said Tuesday.

February 18, 2011

Though efforts to repeal the Patient Protection and Affordable Care Act via the court system remain under way — with recent victories for opponents in Virginia and Florida — the attempt to repeal the healthcare-reform bill in Congress failed, thus leaving the bill and, most importantly, the regulatory approval pathway for follow-on biologics intact.


February 17, 2011

Novartis on Thursday morning named Naomi Kelman head of the Novartis OTC division, effective March 2. She will report directly to Joseph Jimenez, Novartis CEO.

February 11, 2011

The Food and Drug Administration announced Friday the approval of Waltham, Mass.-based Thermo Fisher’s QMS Everolimus Immunoassay, a test that monitors the blood for levels of Novartis’ drug Zortress (everolimus).

February 9, 2011

Sandoz is developing as many as 10 new follow-on biologics, according to published reports.

February 1, 2011

The Food and Drug Administration has approved a Novartis vaccine for preventing meningococcal disease in children, the Swiss drug maker said.

February 1, 2011

SUPPLIER NEWS — The Food and Drug Administration has approved a generic drug made by Watson Pharmaceuticals for cancer-related breakthrough pain, Watson said. The drug is a generic version of Cephalon’s Fentora, which had sales of around $179 million during the 12-month period ended in November 2010, according to IMS Health.


January 27, 2011

Swiss drug maker Novartis posted sales of $14.2 billion for fourth quarter 2010 and $50.6 billion for the year as a whole, according to an earnings report released Thursday.

January 18, 2011

Generic drug maker Sandoz has started a mid-stage clinical trial of a monoclonal antibody used to treat cancer and autoimmune disease, the company said.

January 7, 2011

The Food and Drug Administration has approved a generic contraceptive made by Sandoz, the company said.

January 4, 2011

Par Pharmaceutical has started shipping a generic version of a hypertension drug, the company said Monday.

January 3, 2011

Sandoz has launched higher dosages of its authorized generic version of a hypertension drug, the generics division of Swiss drug maker Novartis said Monday.